News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
834,042 Results
Type
Article (85695)
Company Profile (703)
Press Release (747644)
Section
Business (232279)
Career Advice (4114)
Deals (39660)
Drug Delivery (122)
Drug Development (90707)
Employer Resources (194)
FDA (17978)
Job Trends (17279)
News (395631)
Policy (39626)
Tag
Academia (2974)
Alliances (56562)
Alzheimer's disease (1368)
Approvals (17927)
Artificial intelligence (173)
Bankruptcy (396)
Best Places to Work (12562)
Biotechnology (485)
Breast cancer (197)
Cancer (1467)
Cardiovascular disease (124)
Career advice (3518)
CAR-T (112)
Cell therapy (321)
Clinical research (72016)
Collaboration (527)
Compensation (276)
COVID-19 (2811)
C-suite (120)
Data (1431)
Diabetes (184)
Diagnostics (6705)
Earnings (94799)
Employer resources (167)
Events (127374)
Executive appointments (417)
FDA (18702)
Funding (464)
Gene therapy (225)
GLP-1 (709)
Government (5049)
Healthcare (20746)
Infectious disease (2907)
Inflammatory bowel disease (126)
Interviews (808)
IPO (17651)
Job creations (5180)
Job search strategy (2856)
Layoffs (496)
Legal (10049)
Lung cancer (215)
Manufacturing (234)
Medical device (14440)
Medtech (14445)
Mergers & acquisitions (22161)
Metabolic disorders (518)
Neuroscience (1722)
NextGen Class of 2024 (7649)
Non-profit (5067)
Northern California (1759)
Obesity (293)
Opinion (249)
Patents (130)
People (64377)
Pharmaceutical (142)
Phase I (22202)
Phase II (31272)
Phase III (23569)
Pipeline (530)
Postmarket research (3548)
Preclinical (10010)
Radiopharmaceuticals (256)
Rare diseases (290)
Real estate (7373)
Regulatory (26120)
Research institute (2642)
Resumes & cover letters (649)
Southern California (1511)
Startups (4276)
United States (16421)
Vaccines (662)
Weight loss (227)
Date
Last 7 days (166)
Last 30 days (1673)
Last 365 days (36818)
2025 (101)
2024 (37609)
2023 (42569)
2022 (53928)
2021 (58724)
2020 (57670)
2019 (51341)
2018 (39125)
2017 (37191)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1264)
Arizona (230)
Asia (49525)
Australia (8729)
California (4066)
Canada (1495)
China (340)
Colorado (183)
Connecticut (192)
Europe (113333)
Florida (560)
Georgia (144)
Illinois (458)
Indiana (242)
Maryland (695)
Massachusetts (3238)
Michigan (188)
Minnesota (318)
New Jersey (1176)
New York (1140)
North Carolina (883)
Northern California (1759)
Ohio (154)
Pennsylvania (967)
South America (1648)
Southern California (1511)
Texas (595)
Washington State (438)
834,042 Results for "tevogen bio inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Tevogen Bio Set to Join Russell 3000® Index
Tevogen Bio Holdings Inc. is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24.
June 12, 2024
·
4 min read
Business
Tevogen Bio Reports First Quarter 2024 Financial Results
Tevogen Bio Holdings Inc. has announced financial results for the fiscal quarter ended March 31, 2024, and filed its quarterly report on Form 10-Q with the Securities and Exchange Commission.
May 29, 2024
·
7 min read
Press Releases
Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference
December 10, 2024
·
1 min read
Press Releases
Tevogen Bio’s Effort in Artificial Intelligence, Tevogen AI, Joins Microsoft for Startups, Begins Accelerating drug Development
October 24, 2024
·
6 min read
Pharm Country
Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives
Tevogen Bio Holdings Inc. has entered into a binding term sheet [with an existing investor] to secure up to $50 million of financing.
May 10, 2024
·
6 min read
Drug Development
Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances
Tevogen Bio Holdings Inc. reports publication of its phase I clinical trial data of TVGN 489, its investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes (CTLs) immunotherapy by the journal Blood Advances.
June 25, 2024
·
6 min read
Business
Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives
Tevogen Bio Holdings Inc. announced financial results for full year 2023, business highlights, and upcoming operational objectives.
May 1, 2024
·
7 min read
Pharm Country
Tevogen Bio Holdings Inc., a Cell Therapy Company, Announces Completion of Business Combination and is to be Listed on Nasdaq Under Ticker TVGN
Tevogen Bio Holdings Inc. has announced the completion of Tevogen Bio Inc’s previously announced business combination with Semper Paratus Acquisition Corporation, leading to the formation of Tevogen Bio Holdings Inc.
February 14, 2024
·
7 min read
Pharm Country
Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities
Tevogen Bio Holdings Inc. filed a Registration Statement on Form S-1 on June 21, 2024, to register the issuance of previously disclosed shares of the Company’s common stock as well as the resale of shares of common stock and warrants by existing securityholders.
June 26, 2024
·
3 min read
Business
Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development
Tevogen Bio Holdings Inc announces the appointment of Tapan V Shah as Head of Investor Relations and Corporate Development.
April 3, 2024
·
2 min read
1 of 83,405
Next
